Laggard Doesn't (Always) Mean Loser
Bloomberg Businessweek|May 10, 2021
At least a few companies still in the vaccine race will likely succeed as Covid lingers
Naomi Kresge and Tim Loh, with Suzi Ring and Cristin Flanagan

The Covid-19 vaccine rollout has given drugmakers the kind of brand-name shorthand usually reserved for more mundane consumer products: People talk about getting Pfizer, Moderna, J&J, or Astra much as they might reach for a Kleenex or a Popsicle. And those companies have contracts to provide billions of doses, appearing to leave little room for other entrants. So why are dozens of hopefuls still working on shots?

The answer is that while early leaders stand to book immense profits, the problem is big enough—and the continuing challenges daunting enough—to leave room for at least a few more companies. The offerings of two that got to the market quickly, AstraZeneca Plc and Johnson & Johnson, have been linked to rare blood clots, slowing their rollout. The handling requirements and high cost of the Moderna and Pfizer-BioNTech messenger RNA vaccines mean governments in poorer places would welcome a cheaper, easier-to-ship alternative. And the rise of new variants opens the door to shots that target the evolving coronavirus. “While we’re thrilled with the vaccines that we have, and we’re so lucky that these vaccines turned out to have such high efficacy and a good safety profile, we can improve further,” says Soumya Swaminathan, the World Health Organization’s chief scientist.

Continue reading your story on the app

Continue reading your story in the magazine

MORE STORIES FROM BLOOMBERG BUSINESSWEEKView All

When Employees Go, Data Can Leave, Too

Cybersecurity professionals fear that job cuts can lead to vulnerabilities

3 mins read
Bloomberg Businessweek US
January 23, 2023

The Word That Went Unsaid at Davos

The outlook among global leaders at the World Economic Forum in Davos, Switzerland, in mid-January ranged from cautiously optimistic to unapologetically positive. Attendees interviewed by Bloomberg News during the proceedings talked about the reopening of China, the warmer-than-expected winter, which has helped keep energy prices down, and the expected surge in other commodity prices that hasn't occurred.

2 mins read
Bloomberg Businessweek US
January 30, 2023

Monster Truck

Mercedes makes the G-Wagen bigger, badder and in a way I didn't think possible better.

3 mins read
Bloomberg Businessweek US
January 30, 2023

A Natural Touch For Jewelry

Collectors clamor for Emmanuel Tarpin’s one-of-a-kind pieces.

1 min read
Bloomberg Businessweek US
January 30, 2023

These Watches Are Not for You

Max Büsser and his band of revolutionaries made products they themselves wanted-and built a huge fandom on the way.

4 mins read
Bloomberg Businessweek US
January 30, 2023

INDEPENDENTS DAY

Small watchmakers are soaring thanks to a boom in timepiece: collecting and a supply crunch among the most famous Swiss brands.

10 mins read
Bloomberg Businessweek US
January 30, 2023

FOREVER 18?

Middle-aged tech centimillionaire Bryan Johnson and his team of 30 doctors say they have a plan to reboot his body

10+ mins read
Bloomberg Businessweek US
January 30, 2023

Big Brother at Bargain

NSO Group and its rivals have made military-grade surveillance software shockingly affordable. The way it was used against the real-life hero of Hotel Rwanda might finally force lawmakers' hands

10+ mins read
Bloomberg Businessweek US
January 30, 2023

Trolling While on Autopilot

Amid falling demand and sudden price cuts, Elon Musk seems determined to take a blowtorch to his car company’s brand

10+ mins read
Bloomberg Businessweek US
January 30, 2023

Tackling Textile Waste

A machine that sorts unwearable clothing is helping divert items away from landfill

3 mins read
Bloomberg Businessweek US
January 30, 2023
RELATED STORIES

5 Facts About the New Covid Booster

What you need to know to further protect yourself & your loved ones

2 mins read
Closer US
October 17, 2022

China's Bet On Homegrown mRNA Vaccines Holds Back Nation

China is trying to navigate its biggest coronavirus outbreak without a tool it could have adopted many months ago, the kind of vaccines that have proven to offer the best protection against the worst outcomes from COVID-19.

4 mins read
Techlife News
May 28, 2022

Time for a Boost

As changes to the vaccine policy are announced we unpack what you need to know

6 mins read
YOU South Africa
10 March 2022

MOST EFFECTIVE COVID VACCINES

CDC says mRNA works – China’s jabs are JUNK!

1 min read
Globe
February 21, 2022

MIRACLE COVID DRUG COMES WITH A CATCH!

A BREAKTHROUGH medication has been approved by the FDA to fight COVID-19, but it can cause potentially life-threatening interactions with a variety of widely prescribed drugs, warned experts.

1 min read
National Enquirer
January 31, 2022

Vacuna COVID-19 en niños: soluciona tus dudas

Los pequeños de 5 a 11 años ya pueden vacunarse frente al coronavirus. De la mano de dos expertos en Pediatría, resolvemos algunas cuestiones que preocupan a los padres.

3 mins read
Ser Padres
Issue 552

Dig Into Analysts' Estimates for Disruptive Companies

THE PANDEMIC ERA generated a whole wave of disruptive companies as it accelerated the introduction of new products and services in areas including artificial intelligence, digitization, electronic payments, online meeting platforms, and virtual currencies.

4 mins read
Bloomberg Markets
October - November 2021

The World's 50 Most Innovative Companies – Biotech

Mariana Matus Cofounder and CEO of Biobot Analytics

3 mins read
Fast Company
March - April 2021

Beyond Covid

More uses for new mRNA technology

3 mins read
Reason magazine
May 2021

The Last Pandemic

Technological breakthroughs and policy progress mean humanity may never again have to endure a disaster like Covid-19.

10+ mins read
Reason magazine
May 2021